LONDON, September 14, 2016 /PRNewswire/ --
Norgine today announced that it has launched MUGARD(R), a medical device for the prevention and management of the signs and symptoms of oral mucositis caused by chemotherapy and radiation therapy in Spain. Approximately 177,000 cases of oral mucositis occur each year in Spain.,
(Logo: http://photos.prnewswire.com/prnh/20130829/633895-a )
MUGARD(R) is a mucoadhesive oral rinse proven to prevent and manage the lesions and symptoms of oral mucositis by adhering to the mucosal surface of the mouth and forming a soothing, protective layer. Approximately 20-40% of patients receiving conventional chemotherapy and nearly all patients receiving head and neck radiation therapy suffer from oral mucositis. With limited effective treatment options available, MUGARD(R) has been created for patients to take prior to and during cancer treatment to relieve the signs and symptoms of oral mucositis.
Peter Martin, Chief Operating Officer, Norgine said: "We are delighted to launch MUGARD(R) in Spain as it provides cancer patients with an important treatment for oral mucositis, when we know there are limited effective treatment options available. Managing the side effects of cancer treatment is essential to keeping patients on their cancer therapy."
Norgine holds the rights to MUGARD(R) in Europe, Australia and New Zealand. Norgine anticipates further launches of MUGARD(R) in 2016 and 2017.
You can view the full press release on http://www.norgine.com
Norgine Media Contacts
Isabelle Jouin, T: +44(0)1895-453643
Charlotte Andrews, T: +44(0)1895-453607
Follow us @norgine
1. Norgine data on file. MUGARD 5YP Forecast 2016, July 2016
2. Norgine data on file. Epidemiology-SCP, June 2016
3. Allison RR, Ambrad AA, Arshoun, et al. Cancer 2014; 120(9): 1433-1140
4. Lalla RV, Saunders DP, Peterson DE. Dent Clin North Am 2014; 58(2): 341-9